UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 Enzymes Are Major Determinants of the Androgen Response in Prostate Cancer LNCaP Cells*

Uridine diphosphate-glucuronosyltransferase 2 (UGT2)B15 and B17 enzymes conjugate dihydrotestosterone (DHT) and its metabolites androstane-3α, 17β-diol (3α-DIOL) and androsterone (ADT). The presence of UGT2B15/B17 in the epithelial cells of the human prostate has been clearly demonstrated, and significant 3α-DIOL glucuronide and ADT-glucuronide concentrations have been detected in this tissue. The human androgen-dependent cancer cell line, LNCaP, expresses UGT2B15 and -B17 and is also capable of conjugating androgens. To assess the impact of these two genes in the inactivation of androgens in LNCaP cells, their expression was inhibited using RNA interference. The efficient inhibitory effects of a UGT2B15/B17 small interfering RNA (siRNA) probe was established by the 70% reduction of these UGT mRNA levels, which was further confirmed at the protein levels. The glucuronidation of dihydrotestosterone (DHT), 3α-DIOL, and ADT by LNCaP cell homogenates was reduced by more than 75% in UGT2B15/B17 siRNA-transfected LNCaP cells when compared with cells transfected with a non-target probe. In UGT2B15/B17-deficient LNCaP cells, we observe a stronger response to DHT than in control cells, as determined by cell proliferation and expression of eight known androgen-sensitive genes. As expected, the amounts of DHT in cell culture media from control cells were significantly lower than that from UGT2B15/B17 siRNA-treated cells, which was caused by a higher conversion to its corresponding glucuronide derivative. Taken together these data support the idea that UGT2B15 and -B17 are critical enzymes for the local inactivation of androgens and that glucuronidation is a major determinant of androgen action in prostate cells.

[1]  Hong Liu,et al.  Cloning and characterization of human form 2 type 7 17β-hydroxysteroid dehydrogenase, a primarily 3β-keto reductase and estrogen activating and androgen inactivating enzyme , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  G. Hammond.  Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. , 1978, The Journal of endocrinology.

[3]  N. Olea,et al.  Negative controls of cell proliferation: human prostate cancer cells and androgens. , 1989, Cancer research.

[4]  Pierre Legrand,et al.  Comparison of crystal structures of human type 3 3α‐hydroxysteroid dehydrogenase reveals an “induced‐fit” mechanism and a conserved basic motif involved in the binding of androgen , 2005, Protein science : a publication of the Protein Society.

[5]  M. Green,et al.  Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. , 1997, Pharmacogenetics.

[6]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[7]  J. Simons,et al.  Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Mohamed Helal,et al.  Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. , 2004, The Journal of urology.

[9]  C. Tepper,et al.  Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. , 2006, Cancer research.

[10]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[11]  D. Hum,et al.  Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2B11. , 1998, Biochemical and biophysical research communications.

[12]  O. Barbier,et al.  Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. , 2006, Endocrinology.

[13]  G. Coetzee,et al.  Prostate specific antigen gene regulation by androgen receptor , 2004, Journal of cellular biochemistry.

[14]  D. Hum,et al.  Isolation and Characterization of a Novel cDNA Encoding a Human UDP-Glucuronosyltransferase Active on C19 Steroids* , 1996, The Journal of Biological Chemistry.

[15]  Claes Ohlsson,et al.  Serum Levels of Specific Glucuronidated Androgen Metabolites Predict BMD and Prostate Volume in Elderly Men , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  O. Barbier,et al.  Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans , 2003, Trends in Endocrinology & Metabolism.

[17]  T. Pretlow,et al.  Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. , 2001, DNA and cell biology.

[18]  J. Geller,et al.  Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH) , 1987, Urological Research.

[19]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[20]  T. Pretlow,et al.  Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. , 2000, Gene.

[21]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[22]  G. Bubley,et al.  Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Labrie,et al.  Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. , 1989, Journal of steroid biochemistry.

[24]  J. Labbé,et al.  Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.M300010-JLR200 , 2003, Journal of Lipid Research.

[25]  Peter A. Jones,et al.  Locus-Wide Chromatin Remodeling and Enhanced Androgen Receptor-Mediated Transcription in Recurrent Prostate Tumor Cells , 2006, Molecular and Cellular Biology.

[26]  C. Guillemette,et al.  Glucuronosyltransferase activity in human cancer cell line LNCaP , 1995, Molecular and Cellular Endocrinology.

[27]  M. Augustus,et al.  Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. , 2000, The Journal of urology.

[28]  S. Macleod,et al.  An Allele-Specific Polymerase Chain Reaction Method for the Determination of the D85Y Polymorphism in the Human UDPGlucuronosyltransferase 2B15 Gene in a Case-Control Study of Prostate Cancer , 2000, Annals of Surgical Oncology.

[29]  W. E. Farnsworth,et al.  Androgen of the human prostate. , 1976, Endocrine research communications.

[30]  Tzu-Ming Chu,et al.  Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. , 2006, Molecular endocrinology.

[31]  G. Coetzee,et al.  Androgen receptor‐mediated repression of novel target genes , 2007, The Prostate.

[32]  K. Albertine,et al.  Cloning and characterization of the cDNA and gene for human epitheliasin. , 2001, European journal of biochemistry.

[33]  P. Rennie,et al.  Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. , 2006, Cancer research.

[34]  K. McFann,et al.  Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. , 2005, American journal of physiology. Endocrinology and metabolism.

[35]  H. Samaratunga,et al.  Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. , 2005, Endocrine-related cancer.

[36]  O. Barbier,et al.  Cellular Specific Expression of the Androgen‐Conjugating Enzymes UGT2B15 and UGT2B17 in the Human Prostate Epithelium , 2004, Endocrine research.

[37]  Kazuhiro Suzuki,et al.  Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. , 2006, Cancer detection and prevention.

[38]  A. Bélanger,et al.  Determination of Nonconjugated and Conjugated Steroid Levels in Plasma and Prostate after Separation on C‐18 Columns , 1990, Annals of the New York Academy of Sciences.

[39]  T. Hajdinjak,et al.  Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason Score , 2004, The Prostate.

[40]  M. Green,et al.  Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[41]  R. Bérubé,et al.  Metabolism of DHEA in postmenopausal women following percutaneous administration , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.

[43]  A. Matsumoto,et al.  Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. , 2006, The Journal of clinical endocrinology and metabolism.

[44]  E. Berns,et al.  Androgen‐dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP , 1986 .